> Details

Kronenberg, Florian; Kollerits, Barbara; Kiechl, Stefan; Lamina, Claudia; Kedenko, Lyudmyla; Meisinger, Christa; Willeit, Johann; Huth, Cornelia; Wietzorrek, Georg; Altmann, Maria E.; Thorand, Barbara; Melmer, Andreas; Dähnhardt, Doreen; Santer, Peter; Rathmann, Wolfgang; Paulweber, Bernhard; Koenig, Wolfgang; Peters, Annette; Adham, Ibrahim M.; Dieplinger, Hans

Plasma Concentrations of Afamin Are Associated With the Prevalence and Development of Metabolic Syndrome

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Plasma Concentrations of Afamin Are Associated With the Prevalence and Development of Metabolic Syndrome
  • Contributor: Kronenberg, Florian; Kollerits, Barbara; Kiechl, Stefan; Lamina, Claudia; Kedenko, Lyudmyla; Meisinger, Christa; Willeit, Johann; Huth, Cornelia; Wietzorrek, Georg; Altmann, Maria E.; Thorand, Barbara; Melmer, Andreas; Dähnhardt, Doreen; Santer, Peter; Rathmann, Wolfgang; Paulweber, Bernhard; Koenig, Wolfgang; Peters, Annette; Adham, Ibrahim M.; Dieplinger, Hans
  • Published: Ovid Technologies (Wolters Kluwer Health), 2014
  • Published in: Circulation: Cardiovascular Genetics, 7 (2014) 6, Seite 822-829
  • Language: English
  • DOI: 10.1161/circgenetics.113.000654
  • ISSN: 1942-325X; 1942-3268
  • Origination:
  • Footnote:
  • Description: Background— Afamin is a human plasma vitamin E–binding glycoprotein primarily expressed in the liver and secreted into the bloodstream. Because little is known about (patho)-physiological functions of afamin, we decided to identify phenotypes associated with afamin by investigating transgenic mice overexpressing the human afamin gene and performing large-scale human epidemiological studies. Methods and Results— Transgenic mice overexpressing afamin revealed increased body weight and serum concentrations of lipids and glucose. We applied a random-effects meta-analysis using age- and sex-adjusted baseline and follow-up investigations in the population-based Bruneck (n=826), Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk (SAPHIR; n=1499), and KOoperative Gesundheitsforschung in der Region Augsburg (KORA) F4 studies (n=3060). Mean afamin concentrations were 62.5±15.3, 66.2±14.3, and 70.6±17.2 mg/L in Bruneck, SAPHIR, and KORA F4, respectively. Per 10 mg/L increment in afamin measured at baseline, the number of metabolic syndrome components increased by 19% (incidence rate ratio=1.19; 95% confidence interval [CI], 1.16–1.21; P =5.62×10 −64 ). With the same afamin increment used at baseline, we observed an 8% gain in metabolic syndrome components between baseline and follow-up (incidence rate ratio=1.08; 95% CI, 1.06–1.10; P =8.87×10 −16 ). Afamin concentrations at baseline were highly significantly related to all individual metabolic syndrome components at baseline and at follow-up. This observation was most pronounced for elevated waist circumference (odds ratio, 1.79; 95% CI, 1.54–2.09; P =4.15×10 −14 at baseline and odds ratio, 1.46; 95% CI, 1.31–1.63; P =2.84×10 −11 for change during follow-up) and for elevated fasting glucose concentrations (odds ratio, 1.46; 95% CI, 1.40–1.52; P =1.87×10 −69 and odds ratio, 1.46; 95% CI, 1.24–1.71; P =5.13×10 −6 , respectively). Conclusions— This study in transgenic mice and >5000 participants in epidemiological studies shows that afamin is strongly associated with the prevalence and development of metabolic syndrome and all its components.
  • Access State: Open Access